- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04609813
Esophageal cAncer Screening Trial (EAST)
Esophageal cAncer Screening Trial (EAST) Based on Novel Sponge Cytology:a Multicenter Nationwide Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Esophageal cancer is the seventh most common cancer and the sixth leading cause of cancer related death worldwide in 2020. The highest-incidence areas include Eastern and Central Asia, sub-Saharan Africa, and some South American countries, with esophageal squamous cell carcinoma (ESCC) being the dominant histologic subtype (nearly 90%). While esophageal adenocarcinoma, as a type of adenocarcinoma of the esophagogastric junction (AEG), was less common in these high-risk areas, but accounts for approximately two-thirds of esophageal cancer cases in Europe and North America. However, cardiac gastric cancer, another type of AEG, often shows high incidence in ESCC high-risk areas. Strikingly, 57.5% of global ESCC cases and 60.8% of cardiac gastric cancer cases were estimated to occur in China in 2018. Most esophageal cancer high-risk areas locate in developing countries with limited medical resources, high incidence and co-occurrence ESCC and AEG have posed significant challenges for disease control.
Both ESCC and AEG demonstrate dismal prognosis, with an overall 5-year survival of less than 30%. This is largely due to the asymptomatic nature of early-stage lesions, which frequently leads to delayed diagnosis. Population-based studies in China have confirmed that upper gastrointestinal endoscopy with Lugol's staining could increase the early detection rate and decrease both the incidence and mortality of ESCC and the mortality of AEG in very high-risk areas. However, the invasiveness and resource intensiveness of endoscopic procedure and relative low prevalence of target lesions in the general screening population (0.8% to 1.6%) limit its feasibility and cost-effectiveness in massive screening. Therefore, developing less invasive, readily accessible methods with acceptable diagnostic accuracy is urgently needed for enrichment of high-risk individuals prior to endoscopy. To date, few non-endoscopic preliminary screening methods were available for ESCC and AEG.
The esophageal sponge cytology is an emerging, minimally invasive, and convenient test for esophageal cancer as well as its precancerous lesions and conditions. The expandable sponge could harvest epithelial cells from the entire esophagus and the esophagogastric junction (EGJ) during withdrawn, and subsequent morphological or biomarker analysis could be performed. For Barrett esophagus (BE), the Cytosponge-trefoil factor 3 is a well-established non-endoscopic test, and could increase the detection of BE for 10.6-fold among patients with reflux symptoms in the primary care setting. For high-risk areas, where ESCC is the dominant subtype, several types of sponge cytology tests also gained promising yet preliminary results.
In our previous study, we have developed an artificial intelligence (AI)-assisted sponge cytology test, which automatically indicated potentially abnormal cells for cytologist diagnosis, and found the sensitivity and specificity to be 90.0% and 93.7% in community-based ESCC screening in China. However, the inadequacy of experienced cytologists makes this method still suboptimal for population-based screening, especially for resource-limited areas. Furthermore, AEG, which is also within the detection range of the sponge cytology, has not been investigated in previous studies. Therefore, we conducted the Esophageal cAncer Screening Trial (EAST) to develop and validate a fully-automated machine learning model based on cytological and epidemiological features for ESCC and AEG screening in high-risk areas.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Changhai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- subjects underwent opportunistic endoscopic screening for esophageal cancer;
- aged 40-75 years.
Exclusion Criteria:
- subjects with alarming symptoms including dysphagia, hematemesis, and melena;
- subjects underwent upper endoscopy within 1 year;
- subjects with history of esophageal neoplasia;
- subjects with esophageal-gastric varices or esophageal stenosis;
- subjects with histories of esophageal or gastric surgery;
- subjects with coagulation disorders or taking anticoagulant or antiplatelet agents;
- subjects with other contraindications for upper endoscopy or biopsy;
- subjects with other serious disease or malignant tumor, and the life expectancy is less than 5 years;
- subjects that refuse to cooperate with data collection or sign the informed consent.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Screening population
Participants underwent opportunistic endoscopic screening for esophageal cancer in high-risk regions in China will be enrolled in this study.
Esophageal cell specimen will be collected by esophageal sponge cell collection device (Esoheal 1.0) prior to endoscopic examinations.
|
Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device.
A prediction model will be built based on digital cytopathological features of participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic performance of the sponge cytology-based machine learning model for the main target lesions
Time Frame: through study completion, an average of 1.5 year
|
The main target lesions include high-grade intraepithelial neoplasia and carcinoma of the esophagus and gastroesophageal junction. Diagnostic performance include AUC, average precision, sensitivity, specificity, positive predictive value, and negative predictive value. |
through study completion, an average of 1.5 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic performance of cytologist under AI assistance
Time Frame: through study completion, an average of 1.5 year
|
The main target lesions include high-grade intraepithelial neoplasia and carcinoma of the esophagus and gastroesophageal junction. Diagnostic performance include AUC, average precision, sensitivity, specificity, positive predictive value, and negative predictive value. |
through study completion, an average of 1.5 year
|
Numbers needed to screen
Time Frame: through study completion, an average of 1.5 year
|
Numbers of participants needed to screen to prevent one main target lesion.
|
through study completion, an average of 1.5 year
|
Diagnostic performance of abnormal cell count
Time Frame: through study completion, an average of 1.5 year
|
The main target lesions include high-grade intraepithelial neoplasia and carcinoma of the esophagus and gastroesophageal junction. Diagnostic performance include AUC and average precision. |
through study completion, an average of 1.5 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Zhao-Shen Li, MD, Changhai Hospital
- Principal Investigator: Luo-Wei Wang, MD, Changhai Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
Other Study ID Numbers
- EAST
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...United States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
Clinical Trials on Sponge cytological test
-
N.N. Petrov National Medical Research Center of...RecruitingCervical Cancer | Human Papilloma Virus | Cervical DysplasiaRussian Federation
-
The Christie NHS Foundation TrustNot yet recruiting
-
Oslo University HospitalWithdrawnProstate CancerNorway
-
Indiana UniversityTerminatedDiabetes Mellitus | Bacterial Infections | Wound | Infected Ulcer of SkinUnited States
-
Tampere UniversityEuropean Union; Academy of Finland; Cancer Society of FinlandActive, not recruitingCervical Intraepithelial Neoplasia Grade 2/3Finland
-
AeskuLab Pathology PragueInstitute of Biostatistics and analyses, Ltd.CompletedAlgorithm for Cervix Carcinoma ScreeningCzechia
-
Tampere University HospitalKarolinska Institutet; Tampere University; European UnionEnrolling by invitationCervical Intraepithelial Neoplasia Grade 2/3 | Adenocarcinoma in SituFinland
-
Fifth Affiliated Hospital of Guangzhou Medical...Not yet recruiting
-
Mayo ClinicRecruitingBarrett Esophagus | Esophageal AdenocarcinomaUnited States